Spanish Court Upholds Pfizer's Lipitor Patent
The Court of Appeal of Barcelona found that Pfizer's enantiomer patent, covering the calcium salt contained in Lipitor's active ingredient atorvastatin, is valid. The ruling came in response to a joint challenge from generics makers Laboratorios Cinfa S.A., Kern Pharma S.L., Laboratorios Alter S.A. and Laboratorios Belmac S.A., the company said.
“This is a victory not only for Pfizer, but...
To view the full article, register now.